WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012045703) ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/045703    International Application No.:    PCT/EP2011/067237
Publication Date: 12.04.2012 International Filing Date: 03.10.2011
IPC:
C07K 16/28 (2006.01)
Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35 CH-4056 Basel (CH) (For All Designated States Except US).
CARBALLIDO HERRERA, José M. [ES/CH]; (CH) (For US Only).
HARTLE, Stefan [DE/DE]; (DE) (For US Only).
HEUSSER, Christoph [CH/CH]; (CH) (For US Only).
KLAGGE, Ingo [DE/DE]; (DE) (For US Only).
POLZER, Andrea [DE/DE]; (DE) (For US Only).
SCHWAERZLER, Christoph [AT/CH]; (CH) (For US Only).
WOCHNIK-VELTRUP, Gabriela [DE/DE]; (DE) (For US Only)
Inventors: CARBALLIDO HERRERA, José M.; (CH).
HARTLE, Stefan; (DE).
HEUSSER, Christoph; (CH).
KLAGGE, Ingo; (DE).
POLZER, Andrea; (DE).
SCHWAERZLER, Christoph; (CH).
WOCHNIK-VELTRUP, Gabriela; (DE)
Agent: WOOD, Jonathan; Novartis Pharma Ag Patent Department CH-4002 Basel (CH)
Priority Data:
61/389,916 05.10.2010 US
Title (EN) ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
(FR) ANTICORPS ANTI-IL12RBÊTA1 ET LEUR UTILISATION DANS LE TRAITEMENT DES TROUBLES AUTO-IMMUNS ET INFLAMMATOIRES
Abstract: front page image
(EN)The present invention relates to antibodies that specifically bind to IL12Rβ1, the non- signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNƳ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNƳ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
(FR)La présente invention concerne des anticorps se liant spécifiquement à IL12Rβ1, la chaîne non impliquée dans la transduction du signal des récepteurs hétérodimères IL12 et IL23. La présente invention concerne plus spécifiquement des anticorps spécifiques qui sont des antagonistes de récepteurs IL12 et IL23 pouvant inhiber la production de IFNγ induite par IL12/IL18 dans des cellules sanguines ainsi que des compositions et des méthodes d'utilisation desdits anticorps dans le traitement des troubles pathologiques pouvant être traités par inhibition de la production d'IFNγ, de la signalisation d'IL12 et/ou d'IL23, comme la polyarthrite rhumatoïde, le psoriasis ou les affections intestinales inflammatoires, ou autres troubles auto-immuns et inflammatoires.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)